Labsystems Oy

Cancerforskningsfondet Af 1989

Eeva-Marjatta Salonen

Ettore Appella

Vincent Ellis

Charles Pyke

Michael Ploug

Niels Behrendt

Antti Vaheri

Ann Louring Roldan

Hannele Tapiovaara

Francesco Blasi

Maria Vittoria Cubellis

Peter Kristensen

Ross W Stephens

Maria Teresa Masucci

Wolf-Dieter Schleuning

Keld Dano Slashed

Ebbe Ro Slashednne

Keld Dan&oslash;

Leif R&oslash;ge Lund

Ebbe R&oslash;nne

L&aacute;szlo Patthy

Wd Schleuning

Laszlo Patthy

Leif Ro Lund

Lisbeth Birk Mo Slashedller

Jari P&ouml;ll&auml;nen

Jari Pollanen

Lisbeth Birk M&oslash;ller

Activation of plasminogen to plasmin is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator receptor are provided.

Urokinase-type plasminogen activator receptor

Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.

Vectors and methods for recombinant production of uPA-binding fragments

A method of determining the presence of epithelial lesions is provided wherein a sample of a body of fluid taken from an epithelial region suspected to have said lesions is tested for the presence of a proteolytic activity. The lesion is then treated by applying a therapeutically effective amount of a proteinase inhibitor in the form of a physiologically acceptable preparation, a pharmaceutical preparation of aprotinin being particularly preferred. A method for detecting allergic sensitivity is also disclosed.

Method of ophthalmic testing

A method of determining the presence of epithelial lesions is provided wherein a sample of a body fluid taken from an epithelial region suspected to have said lesions is tested for the presence of a proteolytic activity. The lesion is then treated by applying a therapeutically effective amount of a proteinase inhibitor in the form of a physiologically acceptable preparation, a pharmaceutical preparation of aprotinin being particularly preferred.

Pharmaceutical preparation for promoting epithelial healing and

Method for promoting epithelial healing and prevention of epitheliam

Growing community of inventors

Espoo, Finland

Eeva-Marjatta Salonen